Hanmi Pharmaceutical said Thursday that its new CEO, Hwang Sang-yeon, carried out his first official schedule by visiting the company’s production plants in Paltan and Pyeongtaek, Gyeonggi Province, and its research and development center in Dongtan.
Hwang on Tuesday visited the Paltan Smart Plant, the Pyeongtaek Bio Plant and the Dongtan R&D Center in sequence, inspecting production lines and listening to employees at research sites.
He arrived at the Paltan site at about 7:30 a.m., greeting employees as they came to work. He then checked the information and communications technology-based drug manufacturing process and the radio-frequency identification logistics and delivery system.
At the Pyeongtaek Bio Plant, he toured manufacturing facilities with capacity of up to 12,500 liters and a production line that makes more than 24 million prefilled syringes a year. At the Dongtan R&D Center, he held a meeting with researchers.
Hanmi said Hwang also attended an event on the evening of March 31, his first day in office, for outstanding employees from Beijing Hanmi Pharmaceutical.
After completing his first official schedule, Hwang emphasized to employees his commitment to continuing R&D and quality management based on the late founder and former chairman Lim Seong-gi’s management principles of “respect for humanity” and “value creation.”
“As CEO of Hanmi Pharmaceutical, I will focus on management grounded in law and common sense, and I will do my utmost to ensure we can establish our standing as a global Hanmi,” Hwang said. He pledged “open management centered on the workplace and employees,” and “organic, active discussions among the group’s holding company and affiliates” to pursue advanced management practices.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.